Hikma Pharmaceuticals PLC
LSE: HIK.L0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- London Stock Exchange
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- CEO
- Said Samih Taleb Darwazah
- Employees
- 9,500
- Headquarters
- London, United Kingdom
- IPO year
- 2005
- Market cap
- £3.1B
- Website
- https://www.hikma.com
Loading HIK…
Loading profile data…Frequently asked questions about HIK
What does Hikma Pharmaceuticals PLC (HIK.L) do?
Hikma Pharmaceuticals PLC develops, manufactures, markets, and sells a range of generic, branded, and in-licensed pharmaceutical products. The company offers its products in solid, semi-solid, liquid, and injectable final dosage forms. It operates through three segments: Injectables, Generics, and Branded. The Injectables segment provides generi...
Where does HIK.L trade?
Hikma Pharmaceuticals PLC (HIK.L) trades on the London Stock Exchange.
What sector is HIK.L in?
Hikma Pharmaceuticals PLC (HIK.L) operates in the Healthcare sector, specifically in the Drug Manufacturers - Specialty & Generic industry.
Who is the CEO of Hikma Pharmaceuticals PLC?
Said Samih Taleb Darwazah is the chief executive officer of Hikma Pharmaceuticals PLC (HIK.L).
Where is Hikma Pharmaceuticals PLC headquartered?
Hikma Pharmaceuticals PLC is headquartered in United Kingdom.
Does HIK.L pay a dividend?
Yes — Hikma Pharmaceuticals PLC (HIK.L) paid a trailing twelve-month dividend of GBp 61.80 per share. Frequency and ex-dividend dates are tracked on the dividends tab.
When did HIK.L go public?
Hikma Pharmaceuticals PLC (HIK.L) completed its initial public offering in 2005.